-
Lunsheng Pharmaceutical Announces Positive Preliminary Results of CABP's Phase 3 Lefarmoreline Trial
Time of Update: 2021-07-06
Lunsheng Pharmaceutical, a Chinese biopharmaceutical company that focuses on innovative biomedical research and development in China, and Nabriva Therapeutics, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infectives to treat severe infections, today announced that Lunsheng has acquired bacterial pneumonia in the community ( The Phase 3 bridging trial of Lefamorin in Chinese adult patients of CABP has achieved positive preliminary results .
-
Sihuan Medicine Degu Aspart Double Insulin Injection was approved for clinical use
Time of Update: 2021-07-06
On June 7, the official website of CDE showed that the diabetes drug Degu aspartic insulin injection developed by Jilin Huisheng Biological, a subsidiary of Sihuan Pharmaceutical, was approved for clinical use.
It is the first clinically approved biosimilar drug in China.
-
GlaxoSmithKline sells Innoviva for $392 million
Time of Update: 2021-07-06
" In June 2020, Entasis also completed the second batch of common stock and Innoviva's warrant investment, totaling 35 million U.
-
The 10 billion complement inhibitor market "triples", Alexion's exclusive position was broken; Novartis, Sanofi...
Time of Update: 2021-07-06
A variety of research varieties are already on the way Novartis, Sanofi and others enter the game In addition to the three approved complement inhibitor drugs, there are currently many drugs under development, such as Sanofi’s sutimlimab, Novartis’s iptacopan (LNP023), Vifor Pharmaceuticals/ChemoCentryx’s avacopan (CCX168), Akari’s nomacopan, Achillion's danicopan, Annexon company ANX005, Ra's zilucoplan and so on .
-
Zhenbaodao intends to enter the field of biopharmaceuticals with a 16.67% stake in Terris for 400 million
Time of Update: 2021-07-06
On the evening of June 15th, Zhenbaodao issued an announcement stating that it had signed an investment cooperation agreement with Zhejiang Teruisi Pharmaceutical Co.
Among them, Treasure Island invested 400 million yuan, accounting for 16.
It has 11 innovative drugs and biosimilar products under development.
-
FDA agrees to Phase III pivotal clinical trial of procrulamide for the treatment of hospitalized male and female patients with new crown
Time of Update: 2021-07-06
At the same time, the FDA agreed to expand the inclusion of female patients in the phase III pivotal clinical trial of Prokalamide for mild and moderate new crowns .
-
The compound annual growth rate of the Chinese market for invisible braces exceeds 23%. Why is Angel of Time worth paying attention to?
Time of Update: 2021-07-06
Time Angel provides dentists with comprehensive digital auxiliary case evaluation support, medical treatment plan design services, and technical support, so as to assist dentists in the entire invisible correction process.
-
Boehringer Ingelheim's research therapy for the treatment of cognitive disorders related to schizophrenia has been approved by the U.S. Food and Drug Administration (FDA) as a breakthrough therapy
Time of Update: 2021-07-06
The company also announced plans to launch an innovative phase III CONNEX clinical trial program to evaluate the safety and efficacy of BI 425809 in improving the cognition of adults with schizophrenia .
-
How much money does the new crown vaccine make?
Time of Update: 2021-07-06
It is worth mentioning that if Zhifei Biotechnology achieves the annual sales of 500 million doses of the new crown vaccine, based on the minimum price of a single dose of 50 yuan, its revenue from the vaccine in 2021 will reach 30 billion yuan, exceeding its full-year 2020 15.
-
Deqi Pharmaceuticals announces that Eltanexor Phase I/II clinical trials have completed the first patient with myelodysplastic syndromes
Time of Update: 2021-07-06
today announced that a new generation of selective inhibitor of nuclear export (Selective Inhibitor of Nuclear Export) eltanexor (ATG-016) is an I/ Phase II clinical trial (HATCH) completed the first patient administration in China for the treatment of myelodysplastic syndromes at risk in IPSS-R (Revised International Prognostic Scoring System) that failed demethylation drugs (HMA) treatment (MDS) .
-
The clinical trial application of ASC40 combined with bevacizumab in the treatment of patients with recurrent glioblastoma was accepted by the State Food and Drug Administration
Time of Update: 2021-07-06
announced today that after communicating with the National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab for the treatment of patients with recurrent glioblastoma (rGBM) has been accepted .
-
China Resources Double-Crane: Parecoxib sodium for injection obtained drug registration certificate
Time of Update: 2021-07-06
According to the global drug sales database of 71 countries, in 2020, the global sales of parecoxib sodium for injection will be 269 million US dollars .
-
Novartis Cosentyx is recommended by NICE for the treatment of non-radiological axial spondyloarthritis in adults
Time of Update: 2021-07-06
Recently, according to foreign media reports, Novartis Cosentyx has been recommended by the National Institute of Health and Healthcare (NICE) for the treatment of adult non-radiological axial spondyloarthritis (nr-axSpA) .
-
Bayer Supports Health Science Lecture Enters Beijing Taipusi Street Community
Time of Update: 2021-07-06
This community science lecture specially invited Hu Zhiping, deputy chief physician of the Department of Hepatobiliary Surgery, Peking University People’s Hospital, and Fan Yu, deputy chief physician of the Department of Urology, Peking University First Hospital, to discuss the characteristics of liver cancer for the community residents and the audience participating in the live broadcast.
-
Huadong Medicine's wholly-owned subsidiary medical equipment obtains EU CE certification
Time of Update: 2021-07-06
They are based on the original Perfectha® series products with added lidocaine ingredients.
To a certain extent, it can improve the comfort during the injection process .
-
Innovent will announce multiple clinical data at the 2021 American Society of Clinical Oncology ASCO Annual Meeting
Time of Update: 2021-07-06
Report Type: Poster Report Abstract Number: 8522 Investigator: Professor Gao Shugeng (Chinese Academy of Medical Sciences and Peking Union Medical College)Oncology Field: Colorectal Cancer Title: Preliminary Results of Phase 1b Study of Sintilimab and Fruquintinib in the Treatment of Advanced Colorectal Cancer Report Type: Poster Discussion Abstract Number: 2514 Investigators: Professor Guo Ye, Professor Li Jin (Tongji University East hospital) * this study Cinda biology and medicine and Huang (China) Co.
-
Chenguang Biology has established a research platform for efficacy evaluation and opened to the society
Time of Update: 2021-07-06
is a world leader in the natural pigment industry and an important international supplier of plant extracts.
In order to verify its efficacy, Chenguang Biological invested more than 4 million yuan to build an efficacy evaluation scientific research platform and put it into use in early 2021 .
-
Financing continues to explode frequently, are Internet medical companies such as Kuaiyao "healthy"?
Time of Update: 2021-07-06
In 2014, Renhe Pharmaceuticals invested 5 million yuan in angel round investment to establish Dingdang Kuaiyao, starting with O2O drug delivery business .
After the change of coaching, Ping An Good Doctor launched a "comprehensive strategic upgrade" and launched four new businesses: family doctor services, consumer medical care, health malls, and health interaction and management.
-
Orsendo Biotechnology Innovation Center was unveiled in Shanghai
Time of Update: 2021-07-06
Relying on the platform technology advantages of the innovation center and regional industry collection resources, Orsondor plans to promote dozens of new products (including equipment and reagents) that meet the needs of China's local medical market in the next five years; at the same time, it plans to introduce talents, Increase local and international cooperation and other measures to further enhance the operational level in China and accelerate the construction of a "research-production-sales integrated ecosystem" in the Chinese market .
-
Junshengtai HTD1801 Primary Biliary Cholangitis Phase II Clinical Trial of the First Patient Enrolled in the Group
Time of Update: 2021-07-06
On this basis, We are very much looking forward to the positive results of the Phase II clinical trial for primary biliary cholangitis, which will bring safer and more effective treatment options for patients .
